Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 6/20 | 0.31 |
| ▸ | TDO2 | P48775 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496430 | 0.85 | TBXAS1 (0.36) | TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL8059100 | 0.81 | IDO1 (0.36) | TBXAS1IDO1TDO2 | |
| SCHEMBL7550261 | 0.80 | IDO1 (0.31) | TBXAS1IDO1TDO2 | |
| SCHEMBL7496497 | 0.79 | TBXAS1 (0.30) | TBXAS1 | |
| SCHEMBL7497261 | 0.75 | TBXAS1 (0.39) | TBXAS1 | |
| SCHEMBL8052737 | 0.74 | ALDH1A1 (0.33) | TBXAS1CYP11B1CYP11B2IDO1TDO2 | |
| SCHEMBL8041425 | 0.74 | LMNA (0.33) | TBXAS1 | |
| SCHEMBL7498371 | 0.74 | — | — | |
| SCHEMBL7500293 | 0.73 | ADH1B (0.30) | — | |
| SCHEMBL7499862 | 0.72 | TBXAS1 (0.33) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1022279-B1 | NEW CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-0760370-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA CO (JP) | 2002-08-07 | — | — | EP | disclosed |
| US-6310056-B1 | 2-SUBSTITUTED WITH A IMIDAZO(5,1-B)THIAZOLE GROUP; TREATING INFECTIONS, INCLUDING ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
| EP-1022279-A1 | NEW CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| EP-0669336-B1 | NOVEL CEPHEM DERIVATIVES | MEIJI SEIKA CO (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-5990101-A | Carbapenem derivatives | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-11-23 | — | — | US | disclosed |
| US-5883089-A | BACTERICIDES AND ANTIBIOTICS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-03-16 | — | — | US | disclosed |
| US-5663162-A | BACTERICIDES AND ANTIBIOTICS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0774466-A1 | NOVEL CEPHEM DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0760370-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0669336-A1 | NOVEL CEPHEM DERIVATIVE | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | TBXAS1 4076/4885CYP11B1 2159/4885CYP11B2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.